Feramda Biopharmaceutical Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Out of Business

  • Latest Deal Type
  • Out of Business

Feramda Biopharmaceutical General Information

Description

Developer of safe drugs dedicated to treating wet macular degeneration. The company specializes in creating tellurium-based drugs that inhibit angiogenesis through a unique mechanism of action that increases angiogenesis inhibitors in the eye and inhibits inflammation, enabling medical practitioners to reduce the number of intravitreal anti-vascular endothelial growth factor injections needed for the treatment.

Contact Information

Website
www.feramda.com
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • 4 Kalischer Street
  • Kfar Saba 4438023
  • Israel
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 4 Kalischer Street
  • Kfar Saba 4438023
  • Israel

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Feramda Biopharmaceutical Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Out of Business 01-Jun-2022 Completed Out of Business
1. Seed Round 01-Dec-2018 Completed Generating Revenue
To view Feramda Biopharmaceutical’s complete valuation and funding history, request access »

Feramda Biopharmaceutical Patents

Feramda Biopharmaceutical Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2016224843-A1 Compositions and combinations for the treatment of angiogenesis diseases and disorders Active 26-Feb-2015
AU-2016224843-A8 Compositions and combinations for the treatment of angiogenesis diseases and disorders Active 26-Feb-2015
AU-2016224843-B2 Compositions and combinations for the treatment of angiogenesis diseases and disorders Inactive 26-Feb-2015
AU-2020201620-A1 Compositions and combinations for the treatment of angiogenesis diseases and disorders Inactive 26-Feb-2015
CA-2977738-A1 Compositions and combinations for the treatment of angiogenesis diseases and disorders Inactive 26-Feb-2015 A61K31/095
To view Feramda Biopharmaceutical’s complete patent history, request access »

Feramda Biopharmaceutical FAQs

  • When was Feramda Biopharmaceutical founded?

    Feramda Biopharmaceutical was founded in 2017.

  • Where is Feramda Biopharmaceutical headquartered?

    Feramda Biopharmaceutical is headquartered in Kfar Saba, Israel.

  • What industry is Feramda Biopharmaceutical in?

    Feramda Biopharmaceutical’s primary industry is Drug Discovery.

  • Is Feramda Biopharmaceutical a private or public company?

    Feramda Biopharmaceutical is a Private company.

  • What is Feramda Biopharmaceutical’s current revenue?

    The current revenue for Feramda Biopharmaceutical is .

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process